Poseida’s Solid Tumor CAR-T Shows Early Promise, But Safety Will Be Closely Watched
Promising Signs In Prostate Cancer
Poseida Therapeutics went public in July 2020, but its stock has sunk since then because of CAR-T safety concerns and promise of competing pipeline cancer modalities.
